RxDoctor Payments Data

Wes Triplett, MD

Hematology & Oncology · Sedalia, MONPI 1982800728

Payments from drug & device makers

$4,405in general payments, 2019–2025

Across 35 payments — averaging $125.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$4K
  • Foundation Medicine, Inc.$146
  • Bristol Myers Squibb$125
  • Novartis$98
  • Daiichi Sankyo Inc.$86
  • Sanofi$68
  • plus $264 from 8 others

What the payments were for

  • Food & beverage$75395%
  • Education$385%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,405 in reported general payments places this provider in the 50th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$37,894
Medicare patients
147
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide40$575,418
RevlimidLenalidomide14$266,731
BosulifBosutinib12$165,052
Abiraterone Acetate21$29,726
Oxycodone Hcl44$1,265
Ondansetron Hcl13$1,260
Anastrozole50$487
Prochlorperazine Maleate18$476
Acyclovir37$446
Potassium Chloride31$387
Dexamethasone15$262
Letrozole15$152
Prednisone24$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$125$266,73114 claims
PfizerBosulif$17$165,05212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Sedalia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →